Blood Flow
Conditions
Keywords
Morus Alba L. Extract, Clinical Trial
Brief summary
The effect of 12 weeks intake of Morus alba L. on blood circulation improvement and related indicators is assessed compared to placebo intake.
Detailed description
This study was a 12 weeks, randomized, double-blind, placebo-controlled human trial. Hundred subjects were randomly divided into Morus alba L. extract or a placebo group. Blood was collected and changes in blood circulation related indicators were observed.
Interventions
DIETARY_SUPPLEMENTMorus Alba L. Extract
Morus Alba L. Extract 30 ml/day for 12 weeks.
DIETARY_SUPPLEMENTPlacebo
Placebo 30 ml/day for 12 weeks.
Sponsors
Chonbuk National University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
50 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Those with a fasting total cholesterol of 200\ 239 mg/dL * Those with a fasting LDL-cholesterol of 130\ 159 mg/dL * Those with a fasting blood sugar of 100\ 125 mg/dL * Those with a SBP of 120\ 139 mmHg * Those with a BMI of 25\ 29.9 kg/m\^2 * Waist Hip Ratio (WHR) is 0.9 or more for males and 0.85 or more for females
Exclusion criteria
* Those with platelet aggregation and significant disability * The platelet count is less than 100,000/μL or more than 500,000/μL * The Hematocrit is less than 25% * BMI is less than 18.5kg/m\^2 or greater than 30kg/m\^2 * Those with clinically significant severe cardiovascular, endocrine, immune, respiratory, liver, biliary, renal and urinary tract, neuropsychiatry, musculoskeletal, inflammatory and hematologic and gastrointestinal disorders * Those with a history of clinically significant hypersensitivity to mulberry * Those who have been taking platelet function, blood circulation improvement and hyperlipidemia related medicines, health functional food or herbal medicine continuously for more than 7 days within one month before screening * Those who have received antipsychotic medication within 2 months before screening * Those who participated in other clinical trials within 3 months before screening * Women receiving hormone replacement therapy * Laboratory test by show the following results * AST, ALT \> Reference range 3 times upper limit * Serum Creatinine \> 2.0 mg/dL * Pregnancy or breast feeding * Those who doesn't accept the implementation of appropriate contraception of a childbearing woman * Principal Investigator judged inappropriate for participation in study because of Laboratory test result, etc.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes of Reactive Hyperemia Index | 12 weeks | Reactive Hyperemia Index was measured in study visit 1(0 week) and visit 3(12 weeks). |
| Changes of Platelet function assay | 12 weeks | The whole blood with anticoagulant (sodium citrate) is passed through the capillary and the membrane to assess the degree of platelet adhesion to this membrane and the degree of occlusion of the capillary. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes of Oxidation stress index: Oxidized LDL | 12 weeks | Oxidation stress indices(Oxidized LDL) was measured in study visit 1(0 week) and visit 3(12 weeks). |
| Changes of Lipid peroxidation index: MDA (Malondialdehyde) | 12 weeks | Lipid peroxidation index{MDA(Malondialdehyde)} was measured in study visit 1(0 week) and visit 3(12 weeks). |
| Changes of blood flow indices: PAI-1, t-PA | 12 weeks | Blood flow indices(PAI-1, t-PA) were measured in study visit 1(0 week) and visit 3(12 weeks). |
| Changes of Arteriosclerosis indices: Total cholesterol/HDL-C, LDL-C/HDL-C, Triglyceride/HDL-C, (Total cholesterol-HDL-C)/HDL-C | 12 weeks | It is calculated by the calculation formula using the lipid metabolism indicator test item. |
| Changes of Lipid metabolism indices: Total cholesterol, Triglyceride, LDL-C, HDL-C | 12 weeks | Lipid metabolism indices(Total cholesterol, Triglyceride, LDL-C, HDL-C) were measured in study screening and visit 3(12 weeks). |
| Changes of Pulse wave | 12 weeks | Measured using a pulse wave measuring device (uBioClipTM; BiosenseCreative Co., Ltd., Seoul, Korea) and measured three times, the average value of the measured values is indicated. |
Countries
South Korea
Contacts
Primary ContactSoo Wan Chae, Ph.D., M.D.
Outcome results
None listed